title: Treatment of irritable bowel syndrome: sex and gender specific aspects.
abstract: Patients with functional gastrointestinal disorders constitute the majority of patients seeking healthcare for gastrointestinal symptoms in primary and secondary care. Of these disorders irritable bowel syndrome (IBS) is one of the most common and affects 10-20% in the Western world. IBS is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause. Sex and gender aspects are important in understanding differences between men and women in their risk and experience of IBS. Relative to men, women are diagnosed more frequently with IBS. Female patients are more likely to be constipated, complain of abdominal distension and of certain extracolonic symptoms. Given the variability of IBS, the most successful treatment will be comprehensive, involving multiple strategies. Efficacy, safety and tolerability are important in the evaluation of IBS therapies, as patients are likely to require long-term treatment. Laxatives, antidiarrheals or antispasmodics are common in the treatment of IBS but the majority of patients receive antispasmodics followed by prokinetic agents. In treatment of IBS there appears to be a greater clinical response to serotonergic agents developed for IBS in women compared to men. There is an absence of drugs licensed specifically for the treatment of IBS. Further studies with novel agents are needed, to evaluate new approaches to IBS management including gender specific behavioral therapies and better characterization of patient subgroups with regard to drug therapy so that personalized therapy can be tested.
authors.affiliation: University of Leipzig, Leipzig, Germany.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Voß
authors.forename: Anne
authors.initials: A
authors.lastname: Lewerenz
authors.forename: Karen
authors.initials: K
authors.lastname: Nieber
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D001572:Benzofurans / Q000627:therapeutic use; D005260:Female; D012739:Gonadal Steroid Hormones / Q000502:physiology; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D054368:Laxatives / Q000627:therapeutic use; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D012727:Sex Characteristics
chemical_list: D000928:Antidepressive Agents; D000930:Antidiarrheals; D001572:Benzofurans; D012739:Gonadal Steroid Hormones; D054368:Laxatives; D010276:Parasympatholytics; C406662:prucalopride